Buy. Hold. Earn Rewards. PayPal Unlocks Rewards for Holding PayPal USD
Users to receive 3.7% annually in PayPal USD (PYUSD) for holding the stablecoin on PayPal or Venmo
SAN JOSE, Calif., April 23, 2025 /PRNewswire/ -- PayPal Holdings, Inc. (NASDAQ: PYPL) today introduced rewards for PYUSD1, a new loyalty offering that will provide US users the ability to earn 3.7%2 annually in rewards on holdings of PayPal USD (PYUSD) in their PayPal or Venmo wallets. Available in Summer 2025, PayPal and Venmo3 users will be able to earn rewards on their PYUSD balances, which they can use to pay at millions of merchants, send directly to PayPal and Venmo users, fund remittances on Xoom without transaction fees, convert 1:1 to their fiat balance, convert to other cryptocurrencies, and send onchain to supported wallets on the Ethereum and Solana blockchains.
"At PayPal, we believe stablecoins have the power to reshape the future of commerce as the foundation for the next generation of payments. Combining this innovative technology with our expansive global network allows us to help all users thrive in the world economy," said Alex Chriss, President and CEO, PayPal. "Consumers and businesses use PYUSD today for commerce, crypto, peer-to-peer transfers and B2B payments. We're demonstrating our commitment to an innovative, commerce-ready ecosystem by enabling it for the settlement of cross border transfers, vendor payments and in the future for additional payment use cases like payouts and bill pay."
Users will receive 3.7% annually2 in PYUSD on their PYUSD holdings on PayPal or Venmo. Users can immediately use any rewards received to send to other users, fund international transfers, exchange for fiat, or make purchases at millions of merchants with PayPal Checkout.
Highlights of the offering include:
Commerce-Ready: All PYUSD – purchased and received - can be used seamlessly to fund payments within the PayPal and Venmo ecosystems. Consumers can buy, send, and spend PYUSD both domestically and internationally – giving users additional flexibility and choice in how they use it.
Accrue Rewards Daily, Receive Rewards Monthly: 3.7% annual rewards rate2, awarded out in PYUSD the following month and added directly to the user's Cryptocurrencies Hub.
Users can opt into or opt out of the program at any time and redeem their PYUSD holdings for USD quickly and easily in their PayPal or Venmo Cryptocurrencies Hub.
1 Rewards for PYUSD may not be available to New York State-based users at launch.2 Anticipated rate upon program launch. The PYUSD rewards rate will be determined at all times in PayPal's sole discretion and is not guaranteed. PayPal reserves the right to change the PYUSD rewards rate at any time. Program will be subject to terms and conditions available upon launch.3 Only Venmo consumer accounts are eligible to receive rewards. Venmo Teen Accounts and Venmo Business Profile users are not eligible to participate in the program.
About PayPal USD (PYUSD)PayPal USD is issued by Paxos Trust Company, a fully chartered limited purpose trust company. Paxos and its products – including expansion to new blockchains – are licensed to engage in Virtual Currency Business Activity by the New York State Department of Financial Services. Reserves for PayPal USD are fully backed by U.S. dollar deposits, U.S. Treasuries and similar cash equivalents, and PayPal USD can be bought or sold through PayPal and Venmo at a rate of $1.00 per PayPal USD.
About PayPalPayPal has been revolutionizing commerce globally for more than 25 years. Creating innovative experiences that make moving money, selling, and shopping simple, personalized, and secure, PayPal empowers consumers and businesses in approximately 200 markets to join and thrive in the global economy. For more information, visit https://www.paypal.com, https://about.pypl.com/ and https://investor.pypl.com/.
PYUSD IS NOT INSURED BY THE FDIC, SIPC, OR ANY OTHER PUBLIC OR PRIVATE INSURER, INCLUDING AGAINST CYBER THEFT OR THEFT BY OTHER MEANS. PAYPAL IS A FINANCIAL TECHNOLOGY COMPANY AND NOT A DEPOSITORY INSTITUTION. PYUSD, THE PYUSD REWARDS PROGRAM, AND YOUR CRYPTOCURRENCIES HUBS ARE NOT BANK DEPOSITS OR OTHER DEPOSIT ACCOUNTS. PAYPAL DOES NOT INTEND FOR PYUSD REWARDS TO CONSTITUTE A SECURITIES OFFERING AND PARTICIPATION IN THE LOYALTY PROGRAM IS NOT AN INVESTMENT IN A SECURITIES OFFERING.
PayPal, Inc. (NMLS ID #: 910457) is licensed to engage in Virtual Currency Business Activity by the New York State Department of Financial Services.
Contact: Media Relations, mediarelations@paypal.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/buy-hold-earn-rewards-paypal-unlocks-rewards-for-holding-paypal-usd-302435912.html
SOURCE PayPal Holdings, Inc.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
36 minutes ago
- Yahoo
Investors in Landmark Bancorp (NASDAQ:LARK) have seen decent returns of 36% over the past year
It might be of some concern to shareholders to see the Landmark Bancorp, Inc. (NASDAQ:LARK) share price down 18% in the last month. While that might be a setback, it doesn't negate the nice returns received over the last twelve months. To wit, it had solidly beat the market, up 31%. So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress. This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality. To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. Landmark Bancorp was able to grow EPS by 28% in the last twelve months. This EPS growth is reasonably close to the 31% increase in the share price. That suggests that the market sentiment around the company hasn't changed much over that time. We don't think its coincidental that the share price is growing at a similar rate to the earnings per share. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). Dive deeper into Landmark Bancorp's key metrics by checking this interactive graph of Landmark Bancorp's earnings, revenue and cash flow. It is important to consider the total shareholder return, as well as the share price return, for any given stock. Whereas the share price return only reflects the change in the share price, the TSR includes the value of dividends (assuming they were reinvested) and the benefit of any discounted capital raising or spin-off. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. As it happens, Landmark Bancorp's TSR for the last 1 year was 36%, which exceeds the share price return mentioned earlier. This is largely a result of its dividend payments! It's nice to see that Landmark Bancorp shareholders have received a total shareholder return of 36% over the last year. And that does include the dividend. That's better than the annualised return of 8% over half a decade, implying that the company is doing better recently. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Take risks, for example - Landmark Bancorp has 2 warning signs (and 1 which is a bit unpleasant) we think you should know about. For those who like to find winning investments this free list of undervalued companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. — Investing narratives with Fair Values A case for TSXV:USA to reach USD $5.00 - $9.00 (CAD $7.30–$12.29) by 2029. By Agricola – Community Contributor Fair Value Estimated: CA$12.29 · 0.9% Overvalued DLocal's Future Growth Fueled by 35% Revenue and Profit Margin Boosts By WynnLevi – Community Contributor Fair Value Estimated: $195.39 · 0.9% Overvalued Historically Cheap, but the Margin of Safety Is Still Thin By Mandelman – Community Contributor Fair Value Estimated: SEK232.58 · 0.2% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
36 minutes ago
- Yahoo
Companies Like Zymeworks (NASDAQ:ZYME) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So, the natural question for Zymeworks (NASDAQ:ZYME) shareholders is whether they should be concerned by its rate of cash burn. In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. We'll start by comparing its cash burn with its cash reserves in order to calculate its cash runway. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In March 2025, Zymeworks had US$265m in cash, and was debt-free. Importantly, its cash burn was US$79m over the trailing twelve months. That means it had a cash runway of about 3.4 years as of March 2025. There's no doubt that this is a reassuringly long runway. Depicted below, you can see how its cash holdings have changed over time. View our latest analysis for Zymeworks In the last twelve months, Zymeworks kept its cash burn steady. What was not flat was its operating revenue, which gained 85%. We think it is growing rather well, upon reflection. Clearly, however, the crucial factor is whether the company will grow its business going forward. For that reason, it makes a lot of sense to take a look at our analyst forecasts for the company. We are certainly impressed with the progress Zymeworks has made over the last year, but it is also worth considering how costly it would be if it wanted to raise more cash to fund faster growth. Generally speaking, a listed business can raise new cash through issuing shares or taking on debt. Many companies end up issuing new shares to fund future growth. We can compare a company's cash burn to its market capitalisation to get a sense for how many new shares a company would have to issue to fund one year's operations. Since it has a market capitalisation of US$869m, Zymeworks' US$79m in cash burn equates to about 9.0% of its market value. That's a low proportion, so we figure the company would be able to raise more cash to fund growth, with a little dilution, or even to simply borrow some money. As you can probably tell by now, we're not too worried about Zymeworks' cash burn. In particular, we think its revenue growth stands out as evidence that the company is well on top of its spending. While its increasing cash burn wasn't great, the other factors mentioned in this article more than make up for weakness on that measure. Looking at all the measures in this article, together, we're not worried about its rate of cash burn; the company seems well on top of its medium-term spending needs. On another note, we conducted an in-depth investigation of the company, and identified 2 warning signs for Zymeworks (1 doesn't sit too well with us!) that you should be aware of before investing here. Of course Zymeworks may not be the best stock to buy. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Business Wire
an hour ago
- Business Wire
NeoGenomics Appoints Dr. Marjorie Green to Board of Directors
FORT MYERS, Fla.--(BUSINESS WIRE)-- NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology diagnostic solutions that enable precision medicine, today announced the appointment of Marjorie Green to its Board of Directors, effective June 19, 2025. Dr. Green is currently Senior Vice President and Head of Oncology, Global Clinical Development at Merck. Dr. Green, a seasoned executive with extensive experience in the life sciences industry, brings a strong track record of leadership in oncology, corporate strategy, and business development. As Head of Oncology, Global Clinical Development at Merck, a premier biopharmaceutical company, she oversees the company's research for its single biggest area of commercial revenue and pipeline investment. 'We are thrilled to welcome Marjorie to the NeoGenomics Board,' said Lynn Tetrault, Chair of the Board of NeoGenomics. 'Dr. Green's deep expertise in clinical oncology and pipeline development, combined with her experience in business development, will be invaluable as we continue to accelerate innovation into the precision oncology market.' Prior to joining Merck, Dr. Green served as Senior Vice President and Head of Late-Stage Development at Seagen. Prior to that, Dr. Green was Vice President of Product Development and Global Head of the Breast and Gynecologic Cancer Franchise at Genentech. She began her career as a Medical Oncologist and Associate Professor at MD Anderson Cancer Center where she later became the Medical Director of the Nellie B. Connally Breast Center. Dr. Green earned her BA in History from the University of Notre Dame and her MD from the University of Texas Medical Branch. She completed her residency in internal medicine at the University of Virginia School of Medicine and her medical oncology fellowship at the University of Texas MD Anderson Cancer Center. 'I am honored to join NeoGenomics' Board at such an exciting time in the company's journey,' said Dr. Marjorie Green. 'Neo's unique oncology diagnostics offerings are well positioned for growth, and I look forward to contributing to the company's mission of improving patient care.' About NeoGenomics, Inc. NeoGenomics, Inc. is a premier cancer diagnostics company specializing in cancer genetics testing and information services. We offer one of the most comprehensive oncology-focused testing menus across the cancer continuum, serving oncologists, pathologists, hospital systems, academic centers, and pharmaceutical firms with innovative diagnostic and predictive testing to help them diagnose and treat cancer. Headquartered in Fort Myers, FL, NeoGenomics operates a network of CAP-accredited and CLIA-certified laboratories for full-service sample processing and analysis services throughout the US and a CAP-accredited full-service sample-processing laboratory in Cambridge, United Kingdom. Forward-Looking Statements This press release includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as 'anticipate,' 'expect,' 'plan,' 'could,' 'would,' 'may,' 'will,' 'believe,' 'estimate,' 'forecast,' 'goal,' 'project,' 'guidance,' 'plan,' 'potential' and other words of similar meaning, although not all forward-looking statements include these words. This press release includes forward-looking statements. These forward-looking statements address various matters, including statements regarding improving operational efficiency, returning to profitable growth and its ongoing executive recruitment process. Each forward-looking statement contained in this press release is subject to a number of risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Applicable risks and uncertainties include, among others, the Company's ability to identify and implement appropriate financial and operational initiatives to improve performance, to identify and recruit executive candidates, to continue gaining new customers, offer new types of tests, integrate its acquisitions and otherwise implement its business plan, and the risks identified under the heading "Risk Factors" contained in the Company's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and the Company's other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release. You are encouraged to read our filings with the SEC, available at for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document (unless another date is indicated), and we undertake no obligation to update or revise any of these statements. Our business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.
